Affordable Access

deepdyve-link
Publisher Website

Mapping the Structural Determinants Required for AAVrh.10 Transport across the Blood-Brain Barrier.

Authors
  • Albright, Blake H1
  • Storey, Claire M2
  • Murlidharan, Giridhar1
  • Castellanos Rivera, Ruth M2
  • Berry, Garrett E1
  • Madigan, Victoria J1
  • Asokan, Aravind3
  • 1 Curriculum in Genetics and Molecular Biology, The University of North Carolina at Chapel Hill, Chapel Hill, NC 27599, USA; Gene Therapy Center, University of North Carolina at Chapel Hill, Chapel Hill, NC 27599, USA.
  • 2 Gene Therapy Center, University of North Carolina at Chapel Hill, Chapel Hill, NC 27599, USA.
  • 3 Gene Therapy Center, University of North Carolina at Chapel Hill, Chapel Hill, NC 27599, USA; Department of Genetics, University of North Carolina at Chapel Hill, Chapel Hill, NC 27599, USA; Department of Biochemistry and Biophysics, The University of North Carolina at Chapel Hill, Chapel Hill, NC 27599, USA. Electronic address: [email protected]
Type
Published Article
Journal
Molecular Therapy
Publisher
Elsevier
Publication Date
Feb 07, 2018
Volume
26
Issue
2
Pages
510–523
Identifiers
DOI: 10.1016/j.ymthe.2017.10.017
PMID: 29175157
Source
Medline
Keywords
Language
English
License
Unknown

Abstract

Effective gene delivery to the CNS by intravenously administered adeno-associated virus (AAV) vectors requires crossing the blood-brain barrier (BBB). To achieve therapeutic CNS transgene expression, high systemic vector doses are often required, which poses challenges such as scale-up costs and dose-dependent hepatotoxicity. To improve the specificity and efficiency of CNS gene transfer, a better understanding of the structural features that enable AAV transit across the BBB is needed. We generated a combinatorial domain swap library using AAV1, a serotype that does not traverse the vasculature, and AAVrh.10, which crosses the BBB in mice. We then screened individual variants by phylogenetic and structural analyses and subsequently conducted systemic characterization in mice. Using this approach, we identified key clusters of residues on the AAVrh.10 capsid that enabled transport across the brain vasculature and widespread neuronal transduction in mice. Through rational design, we mapped a minimal footprint from AAVrh.10, which, when grafted onto AAV1, confers the aforementioned CNS phenotype while diminishing vascular and hepatic transduction through an unknown mechanism. Functional mapping of this capsid surface footprint provides a roadmap for engineering synthetic AAV capsids for efficient CNS gene transfer with an improved safety profile. Copyright © 2017 The American Society of Gene and Cell Therapy. Published by Elsevier Inc. All rights reserved.

Report this publication

Statistics

Seen <100 times